Visior Technologies

Company Overview

Snapshot

Founded in January 2013 by Ilan Vadai, Yuval Avni, and Hans Brocker, Visior Technologies operates with 1–10 employees. The company is currently in a Pre-Funding stage and has developed a clinical-stage medical device. In January 2019, research was published on the effects of their image brightness and contrast dynamic altering stimuli when viewing video content on ocular blood flow.

Business overview

Visior Technologies is a clinical-stage medical device company specializing in Health Tech & Life Sciences. The company has developed a commercial video-based noninvasive platform that delivers visual and auditory stimulation to induce changes in cerebral and retinal blood flow, perfusion, and neural connectivity reconstruction in the visual system. This stimulation aims to complement existing medication treatments and enable new modalities for neurodegenerative conditions, serving the Digital Healthcare and Digital Therapeutics sectors.

Strategic signal

In January 2019, a study published in bjo.bmj.com highlighted the effects of Visior Technologies' image brightness and contrast dynamic altering stimuli (DAS) on ocular blood flow when viewing video content. This research signals the company's commitment to validating the physiological impact of its technology, providing a scientific basis for its non-invasive treatment approach in ophthalmology and neurodegenerative conditions.

Company Intelligence Q&A

What is the primary focus of Visior Technologies' medical device?

Visior Technologies' medical device focuses on delivering video-based noninvasive visual and auditory stimulation to induce changes in cerebral blood flow, brain perfusion, retinal blood flow, retinal perfusion, and reconstruct neural connectivity in the visual system.

When was Visior Technologies founded and by whom?

Visior Technologies was founded in January 2013 by Ilan Vadai, Yuval Avni, and Hans Brocker.

What was the finding of the study published in January 2019?

In January 2019, a study published in bjo.bmj.com detailed the effects of Visior Technologies' image brightness and contrast dynamic altering stimuli (DAS) when viewing video content on ocular blood flow.

What was the outcome of the pilot study published in January 2018?

In January 2018, a pilot study published in ncbi.nlm.nih.gov investigated the home use of a binocular dichoptic video content device for the treatment of amblyopia.

What is the current status of Visior Technologies?

Visior Technologies is currently in a Non Active status, having ceased to operate in September 2023.